遗传性纤维蛋白原Aα链淀粉样变性的肾脏结局
该研究纳入194例确诊的遗传性纤维蛋白原Aα链(AFib)淀粉样变性患者,按2009年前后诊断分层,评估诊断方法、肾脏结局、移植结局和生存。结果显示2009年后肾存活改善,肾移植中位存活从7.7年提高至15.5年,但总体生存无显著差异。
要点
- 2009年后肾存活改善,尤其CKD IIIA或B期患者
- 肾移植中位存活从7.7年提高至15.5年(P=0.006)
- 总体生存无显著差异,中位12年
核心结论
- 2009年后肾脏和移植肾存活改善,可能反映支持性肾脏护理进步。
- 孤立肾移植与良好长期结局相关。
- 总体生存未变,凸显需要有效的淀粉样蛋白靶向治疗。
研究设计与样本
- 回顾性队列研究,纳入194例1993至2025年诊断的AFib淀粉样变性患者。
- 按诊断年代(2009年前后)分层,评估诊断方法、肾脏结局、移植结局和患者生存。
主要发现
- 诊断时中位年龄60岁,平均eGFR 37 ml/min per 1.73 m2。
- 2009年后基于蛋白质组学的淀粉样蛋白分型成为主要诊断方法(60.5%)。
- 62.8%进展至终末期肾病(ESRD)。
- 2009年前年均eGFR下降6.7 ml/min per 1.73 m2,2009年后为4.8 ml/min per 1.73 m2。
- 肾移植中位存活从7.7年提高至15.5年(P=0.006;HR 4.5,95%CI 1.2-22.6)。
临床怎么用
- 对AFib淀粉样变性患者应重视支持性肾脏护理以延缓ESRD。
- 孤立肾移植可考虑,长期结局良好。
- 仍需探索淀粉样蛋白靶向治疗以改善总体生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hereditary fibrinogen A alpha-chain (AFib) amyloidosis is characterized by progressive proteinuric chronic kidney disease (CKD) and early progression to end-stage renal disease (ESRD). A large series published in 2009 showed renal survival <5 years from diagnosis and renal transplant survival of <10 years. Since then, advances in diagnostic techniques and nephroprotective care have transformed both nephrology and amyloidosis. We evaluated contemporary diagnostic and renal outcomes in the largest cohort of patients with AFib amyloidosis to date. METHODS: A total of 194 patients with confirmed AFib amyloidosis who were followed at a large national center and diagnosed between 1993 and 2025 were included. Patients were stratified by the era of diagnosis, pre- or post-2009. Diagnostic approaches, renal outcomes, transplant outcomes, and patient survival were evaluated. RESULTS: Median age at diagnosis was 60 years with mean estimated glomerular filtration rate (eGFR) of 37 ml/min per 1.73 m2. Proteomics-based amyloid typing became the predominant diagnostic modality post-2009 (60.5%). 62.8% progressed to ESRD. The mean annual rate of eGFR decline was 6.7 ml/min per 1.73 m2 in the pre-2009 era and 4.8 ml/min per 1.73 m2 in the post-2009 era. Renal survival improved post-2009, particularly among patients with CKD stage IIIA or B at diagnosis. Median renal allograft survival improved from 7.7 years in the pre-2009 era to 15.5 years in the post-2009 era (P = 0.006) (hazard ratio [HR], 4.5 [95% confidence interval [CI], 1.2-22.6]). Overall patient survival did not differ significantly between eras (median, 12 years; P = 0.69, log-rank). CONCLUSIONS: Renal and allograft survival have improved since 2009, likely reflecting advances in supportive nephrology care. Isolated kidney transplantation is associated with favorable long-term outcomes. Despite improvements in renal survival, overall survival remains unchanged, underscoring the need for effective amyloid-targeted therapies.
引用
- Carruthers JE, Rauf MU, Goodman H, et al. Renal Outcomes in Hereditary Fibrinogen A Alpha-Chain Amyloidosis. Kidney Int Rep. 2026. PMID: 42890350. doi:10.1016/j.ekir.2026.107076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。